Search
for
Sort by
Research 91–120 of 1000+
- EFFICACY AND SAFETY OF STANDARDIZED CINNAMON BARK EXTRACT FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED WEIGHT LOSS AND ALOPECIA IN PATIENTS WITH BREAST CANCER: A RANDOMIZED, DOUBLE-BLIND, AND PLACEBO-CONTROLLED STUDY
- Phase II trial of paclitaxel poliglumex (CT-2103) in pre- and post-menopausal women on hormonal replacement therapy (HRT) with non-small cell lung cancer (NSCLC).
- Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody–drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology
- Cancer-Related Alopecia Risk and Treatment
- Trichology to predict efficacy of scalp cooling: New pathologic insights besides encouraging clinical results.
- Systems for Mitochondria-Protective Cosmetic Actives: Opportunities in Post-Oncologic Skin Regeneration
- The Comparative Safety of Epirubicin and Cyclophosphamide versus Docetaxel and Cyclophosphamide in Lymph Node-Negative, HR-Positive, HER2-Negative Breast Cancer (ELEGANT): A Randomized Trial
- Effectiveness and safety of baricitinib in severe alopecia areata: 48‐week results
- Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea
- Incidence and management of cutaneous toxicities associated with cetuximab
- Efficacy and safety of trastuzumab deruxtecan in the treatment of HER2-low/positive advanced breast cancer: a single-arm meta-analysis
- Discrimination and Proper Use of Polygoni Multiflori Radix, Cynanchi Wilfordii Radix, and Cynanchi Auriculati Radix in Korea: A Descriptive Review
- The Facelift
- Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
- Safety assessment of cyclin-dependent kinase 4/6 inhibitors and comparison of time to adverse events
- Real-world safety of Tepotinib: Insights from the Food and Drug Administration Adverse Event Reporting System
- Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China
- Safety of Alopecia Treatments in Patients with Breast Cancer and High-Risk Women: A Review
- Efficacy and Safety of Baricitinib in Patients With Alopecia Areata: A Real‐World Cohort Study
- Safety concerns of paternal drug exposure on fertility, pregnancy and offspring: An analysis based on the FDA adverse event reporting system
- Safety of Antiandrogens for the Treatment of Female Androgenetic Alopecia with Respect to Gynecologic Malignancies
- Tyrosine Kinase Inhibitors against Cancer: Their Safety in 216 Moroccan Patients
- Scalp Lifting
- Testosterone Pellets in Women: Revisiting Safety and Clinical Outcomes
- Laser-Assisted Drug Delivery: A Systematic Review of Safety and Adverse Events
- In Vitro Stability and Preclinical Safety Evaluation of High-Dose Intravitreal Topotecan in Rabbits: Impact of Dose and Concentration
- Trailing the Path to Preventive Oncology
- Impact of anticancer therapy on the quality of life of Sudanese patients with breast cancer at Khartoum oncology hospital
- The investigation of the efficacy and safety of stromal vascular fraction in the treatment of nanofat-treated acne scar: a randomized blinded controlled clinical trial
- Extracellular Vesicles in Regenerative and Cosmetic Medicine: Safety, Clinical Effectiveness, Therapeutic Applications, and Regulatory Challenges